Rash with itching/ I was covered in itchy rash; overall itching after the Pfizer Vaccine/ I was covered in itchy rash; disrupts sleep; disrupts sleep and quality of life; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A 70 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 01Mar2021 10:30 (Lot number: EN6200) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Enlarged Prostate" (ongoing), notes: Onset date: 4 years ago, Pertinent details: None; "Surgery: Spinal surgeries", start date: 2019 (ongoing), notes: Repair 2019; "Surgery: Disc repair", start date: 2017 (ongoing), notes: Repair 2017; "Surgery: Fusion", start date: 2011 (ongoing), notes: Repair 2011; "Prevention" (ongoing), notes: start date : 15 years; "Hypertrophy prostate" (ongoing), notes: Start date: 4 years. Concomitant medication(s) included: ASA EG taken for prophylaxis (ongoing); ALRUBICIN taken for benign prostatic hyperplasia (ongoing). Vaccination history included: Bnt162b2 (Dose 1, Anatomical site of injection: left arm, Route of administration: Intramuscular, Batch/Lot number: EN5318, Time: 10:30 AM), administration date: 08Feb2021, for Covid-19 Immunization, reaction(s): "No adverse reaction". The following information was reported: PRURITUS (non-serious) with onset 02Mar2021, outcome "not recovered", described as "overall itching after the Pfizer Vaccine/ I was covered in itchy rash"; RASH PRURITIC (non-serious) with onset 02Mar2021 08:00, outcome "not recovered", described as "Rash with itching/ I was covered in itchy rash"; SLEEP DISORDER (non-serious) with onset 2021, outcome "unknown", described as "disrupts sleep"; QUALITY OF LIFE DECREASED (non-serious) with onset 2021, outcome "unknown", described as "disrupts sleep and quality of life". The events "overall itching after the pfizer vaccine/ i was covered in itchy rash" and "rash with itching/ i was covered in itchy rash" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of pruritus, rash pruritic.  Additional Information: Vaccination facility type was reported as other. Prior Vaccinations (within 4 weeks) was none. Reporter stated patient had reported overall itching after the Pfizer Vaccine. Per MD, most likely related or unrelated to vaccine due no other findings on work up. It was reported that patient was a 70 YO Male with hx of Prostate Hypertrophy who received two doses of Pfizer COVID 19 vaccine. It was reported that on 08Feb2021 the patient received his 1st vaccine and there was no adverse reaction. On 01Mar2021, the patient received his 2nd vaccine, 24 hours later he was covered in itchy rash. Patient awakened to a rash and pruritus on day after second dose on 01Mar2021. After a week he decided to go to a Dermatologist. He was prescribed creams and pills (but no success). Went on to see 5 more doctors (and again no success). He had been living with this 5 or 11 months now. At 2 month he called Pfizer but they denied knowing anything about a rash. At 6 months, he called Pfizer again and they admitted some cases like his but had no solution. Patient stated he had been evaluated by multiple disciplines and various therapies have been tried, without success. Patient stated he continued to experience pruritus and rash which disrupts sleep and quality of life and would like Pfizer to let him know what to do or if there was a study for patients experiencing this type of reactions after the COVID 19 vaccine. Patient stated he would like to be contacted and provide further guidance to him and his health care team on how to best manage his symptoms. Patient advised to reach out to HCP. Further advised to seek emergency care as needed. The patient received Prednisone tabs for 40 days/ Calamine lotion / Four IV therapy sessions to purify the blood as treatment for events. Specific relevant test for Thromboembolic events with Thrombocytopenia was none. Relevant tests and specific relevant tests were none. No Other information was provided.  Follow-up attempts are completed. No further information is expected.